Save for clinic
📖 Full analysis: >Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications
🎯 Clinical Bottom Line
A de-escalated regimen of 12 weeks of weekly paclitaxel plus 1 year of trastuzumab — without anthracyclines — achieved outstanding disease-free survival in patients with small, node-negative, HER2-positive breast cancer. Only 12 events occurred among 406 treated patients, far exceeding the prespecified efficacy threshold. This trial established the preferred adjuvant regimen for low-risk HER2-positive early breast cancer, sparing patients the toxicity of anthracycline-based polychemotherapy.
Key Result: 3-year survival free from invasive disease — 98.7% (95% CI 97.6–99.8); P<0.001 vs null hypothesis of 9.2% 3-year event rate
Safety Signal: Symptomatic CHF in 2 patients (0.5%), both reversible; grade 3 neuropathy in 13–14 patients (3.2%–3.4%); zero treatment-related deaths.
✅ Patient Eligibility
Must Have:
- HER2-positive breast cancer (IHC 3+ or FISH HER2/CEP17 ratio ≥2.0)
- Adjuvant setting — surgery completed
- Invasive tumor ≤3 cm
- Node-negative (N0) or one lymph-node micrometastasis (N1mic) with completed axillary dissection
- LVEF ≥50%
Cannot Have:
- Node-positive disease (beyond isolated micrometastasis)
- Tumor >3 cm
- Prior systemic therapy for breast cancer
💊 Dosing Quick Guide
Treatment Regimen
Paclitaxel: 80 mg/m² IV weekly × 12 weeks Trastuzumab: 4 mg/kg IV loading dose (day 1) → 2 mg/kg IV weekly × 12 weeks (concurrent with paclitaxel) → then 6 mg/kg IV every 3 weeks (or weekly) × 40 weeks Cycle: 7 days (weekly dosing during combination phase); 21 days (q3w option during trastuzumab monotherapy phase) Duration: 52 weeks total
No comparator arm in this study.
Key Dose Modifications [2]
Per FDA prescribing information — not trial protocol - LVEF decline: Withhold trastuzumab for ≥16% absolute decrease from baseline or LVEF below institutional lower limits of normal; discontinue if not improved within ~4–8 weeks - Cardiac monitoring: LVEF assessment at baseline, every 3 months during therapy, and every 6 months for at least 2 years after completion - Neuropathy: Dose-reduce or hold paclitaxel for grade ≥2 peripheral neuropathy per institutional guidelines
⚠️ Safety Snapshot
| Grade ≥3 Toxicities | Paclitaxel + Trastuzumab (n=406) |
|---|---|
| Neutropenia — Grade 3 | 15 (3.7%) |
| Neutropenia — Grade 4 | 2 (0.5%) |
| Neuropathy — Grade 3 | 14 (3.4%) |
| Leukopenia — Grade 3 | 10 (2.5%) |
| Fatigue — Grade 3 | 9 (2.2%) |
| Hyperglycemia — Grade 3 | 7 (1.7%) |
| Elevated ALT — Grade 3 | 7 (1.7%) |
| Allergic reaction — Grade 3 | 6 (1.5%) |
| Allergic reaction — Grade 4 | 1 (0.2%) |
| Diarrhea — Grade 3 | 6 (1.5%) |
⚠️ Cardiac toxicity:
- Symptomatic CHF (grade 3): 2 (0.5%; 95% CI 0.1–1.8) — both recovered after trastuzumab discontinuation
- Asymptomatic LVEF decline leading to trastuzumab interruption: 13 (3.2%; 95% CI 1.7–5.4)
⚠️ Neuropathy (grade 3): 13 (3.2%; 95% CI 1.7–5.4) during 12-week combination phase; grade 4: 0 (0%; 95% CI 0–0.9)
Key safety metrics:
-
Treatment-related deaths: 0
-
Discontinuations due to toxicity: 24 (protocol-specified) + 6 (other toxic effects)
- Treatment completion: 356 (87.7%) completed all 52 weeks
📊 Key Numbers
Median follow-up: 4.0 years (maximum 6.2 years)
| Outcome | Result (95% CI) | Events / N |
|---|---|---|
| 3-year survival free from invasive disease (primary) | 98.7% (97.6–99.8) | 12 / 406 |
| 3-year recurrence-free interval (exploratory) | 99.2% (98.4–100) | Not reported separately |
Statistical test: Null hypothesis of 9.2% 3-year event rate rejected; P<0.001 (group-sequential Poisson test)
Deaths: 2 (0.5%) — both unrelated to breast cancer (ovarian cancer at 13 months; stroke at 71 months). Zero breast-cancer-related deaths.
🔬 Key Comparator Context
| Trial | Regimen | Population | Primary Endpoint | Key Result | Ref |
|---|---|---|---|---|---|
| APT | Paclitaxel + trastuzumab (no anthracycline) | HER2+ early BC, ≤3 cm, node-neg (adjuvant) | 3-year DFS | 98.7% (95% CI 97.6–99.8); P<0.001 vs null | [1] |
| APHINITY | Pertuzumab + trastuzumab + chemo vs placebo + trastuzumab + chemo | HER2+ early BC, node-pos or high-risk node-neg (adjuvant) | 3-year IDFS | See [4] | [4] |
| BCIRG 006 | AC→TH vs TCH vs AC→T | HER2+ early BC, higher risk (adjuvant) | DFS | See [5] | [5] |
Cross-trial comparisons are limited by differences in populations, designs, and endpoints. APT enrolled a lower-risk population than APHINITY or BCIRG 006.
🔍 Subgroups to Watch
Subgroup analyses by tumor size and hormone-receptor status showed uniformly excellent outcomes:
Tumor ≤1 cm (n=201): 3-year DFS lower boundary of 95% CI exceeded 96.0% Tumor >1 cm (n=205): 3-year DFS lower boundary of 95% CI exceeded 96.0% Hormone-receptor–positive (n=272): 3-year DFS lower boundary of 95% CI exceeded 96.0% Hormone-receptor–negative (n=134): 3-year DFS lower boundary of 95% CI exceeded 96.0%
All subgroups showed recurrence rates lower than anticipated, with excellent outcomes regardless of tumor size (within ≤3 cm) or hormone-receptor status.
Subgroup analyses were not powered for formal comparisons. Results are hypothesis-generating.
📋 Regulatory Status
| Region | Status |
|---|---|
| FDA | Trastuzumab approved for adjuvant HER2+ breast cancer; APT regimen is off-label but widely adopted and guideline-endorsed [2] |
| EMA | Trastuzumab approved for early HER2+ breast cancer; specific APT regimen not named in label |
⚠️ Verify current regulatory status before prescribing.
NCCN: Paclitaxel + trastuzumab (APT regimen) is a preferred adjuvant regimen for small (≤2 cm preferred, up to 3 cm), node-negative, HER2-positive breast cancer (Category 2A) [3]
⚡ Grey Zones
- Single-arm design — the incremental benefit of adding trastuzumab to paclitaxel in this low-risk population cannot be quantified without a comparator arm
- Tumors >3 cm and node-positive disease were excluded — do not extrapolate these results to higher-risk patients
- Whether the smallest tumors (T1a, ≤0.5 cm) truly need any chemotherapy + trastuzumab or could be managed with observation ± endocrine therapy alone is unknown
- Long-term cardiac and recurrence outcomes beyond 4 years are not reported in this publication (10-year follow-up planned)
- Optimal treatment after recurrence on the APT regimen is undefined given only 12 events total
- The role of adding pertuzumab to the APT backbone is untested and likely unnecessary given the already excellent outcomes
📖 Full Analysis
Read the complete desktop article with full efficacy tables, safety detail, event breakdown, subgroup data, comparator trials, and clinical implications at kill-cancer.com
About the Author
Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.
📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum
For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.
References
- Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372:134-141. doi:10.1056/NEJMoa1406281
- Herceptin (trastuzumab) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
- von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122-131. doi:10.1056/NEJMoa1703643
- Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273-1283. doi:10.1056/NEJMoa0910383